Innovative Strategies for Cancer Care

Innovative Strategies for Cancer Care

• 1. Investor Day • 2024 Oncology and Haematology David Fredrickson, EVP, Oncology Business Susan Galbraith, EVP, Oncology R&D Cristian Massacesi, CMO & Oncology Chief Development Officer Anas Younes, SVP, Global Head of Haematology, Oncology R&D Sunil Verma, SVP, Global Medical Affairs Matt Hellmann, VP, Early Oncology Development

• 2. Investor Day • 2024 Forward looking statements 2 In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures (including the Financial Ambition Statements described in this presentation). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that “FPI-2265” (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable, or at all, or that eneboparatide (‘AZP-3601’) will receive the necessary regulatory approvals or prove to be commercially successful if approved. This presentation includes references to new molecular entities and life-cycle management programmes that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For a list of new molecular entities and indications in development, see pages 7-11 of the Clinical Trials Appendix that accompanied AstraZeneca’s Q1 2024 results. Basis of AstraZeneca ambitions, forecasts and targets AstraZeneca ambitions, forecasts and targets in this presentation (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. Financial Ambition Statements presented are based on management’s risk-adjusted projections for individual medicines and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. The peak year revenue (PYR) potential for individual medicines referred to in this presentation are the maximum estimated Total Revenue to be recognised by AstraZeneca in a single calendar year, during the lifecycle of the medicine, and are based on management’s latest non-risk adjusted forecast estimates. Estimates are based on customary forecasting methodologies used in the pharmaceutical industry. Peak year revenue may occur in different years for each NME depending on trial outcomes, approval label, competition, launch dates and exclusivity periods, amongst other variables. The peak year revenue figures are derived from net sales at nominal values and are not risk-adjusted or time-value discounted. The development of pharmaceutical products has inherent risks given scientific experimentation and there are a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not achieve the desired product profile and competitive environment, pricing and reimbursement may have material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary, significantly and materially, from these assumptions. The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates; AZ undertakes no obligation to update those statements based on future currency movements

• 3. 3 Investor Day • 2024 1. 5 million patients across G7 markets (US, UK, FR, DE, IT, ES, JP) and China. 2. Solid tumours: new cases: Globocan; survival rates: 3. American Cancer Society. Haematology: new cases: Cerner Enviza, survival rates (PFS/EFS): literature review. Acronym definitions can be found in Glossary. Unmet need in cancer remains a global challenge Five million new cancer patients diagnosed globally1 per year with low 5-year survival 1L 5yr survival Solid tumours2 New cases (‘000), 2022 G7 China 600k 650k 600k 200k 150k 130k 60k 1,050k 350k 130k 350k 370k 80k 60k 110k 70k 40k 40k 10k 40k 20k 20k 10k 10k 1L 5yr survival Haematology3 New cases (‘000), 2022 G7 China Lung Breast Gastric Liver Endo Ovarian Prostate DLBCL/ FL MM CLL B-ALL AML 50% 55% 10% 35% / 85% adult paed. 70% 5-10% 30% 30% 5-10% <5% 15-20% 30%

• 4. Investor Day • 2024 Critical trends in transforming cancer treatment 4 ADC = Antibody drug conjugates; IO = immuno-oncology. Acronym definitions can be found in Glossary. 1 Replace the backbone of chemotherapy and radiotherapy Novel IO 1 Next wave of IO agents will segment the IO-sensitive space 1 Scalable, accessible therapies in both liquid and solid tumours Powerful combinations 1 Transform outcomes with novel ADC, Radioconjugate and next-generation IO combinations Early intervention 1 Improve long-term outcomes with neoadjuvant combinations 2 3 4 5 1 Cell therapy and T-cell engagers Novel ADCs and Radioconjugates

• 5. Investor Day • 2024 Our strategy to transform patient outcomes 5 Attack cancer from multiple angles Treat earlier and smarter Lead with innovative technology Treatment journey today Future treatment journey Data and AI in clinical trials HER2 TROP2 Accelerating computational pathology Improving patient outcomes through digital health Acronym definitions can be found in Glossary.

• 6. Investor Day • 2024 Powerful combinations to transform survival in cancer 6 Acronym definitions can be found in Glossary. Debulk tumour with ADCs or Radioconjugates, clear micro-metastatic disease with cell therapy or T-cell engagers ADCs and Radioconjugates potential to replace systemic chemotherapy, combine with novel IO bispecifics PARP1 inhibitors to potentiate clinical benefit of ADCs and Radioconjugates Kill cancer cells, debulk tumour and activate immune system with checkpoint inhibitors ADCs Radioconjugates IO bispecifics Enhance immune system when checkpoint inhibition alone is insufficient T-cell engagers CAR-Ts

• 7. Investor Day • 2024 We are leading the ADC revolution to replace systemic chemotherapy 7 1. AZ internal estimates. G7 proportion of patients treated with Chemotherapy CancerMPact®, Cerner Enviza. 2. AGA actionable genomic alterations in NSCLC (e.g. EGFR, ALK, ROS1, RET, MET, NTRK, BRAF). Acronym definitions can be found in Glossary. Estimated number of patients treated with ADCs at peak (est. G7, 000s)1 Significant potential ADC opportunity across multiple tumours AstraZeneca robust ADC portfolio with proven execution Combination opportunities with IO and DDR Strong foundation in ADCs Six clinical-stage internal ADCs B7H4 • CLDN18.2 • CD123 EGFR/cMET • GPRC5D • FRα 2 2

• 8. Investor Day • 2024 10 40 70 100 90 80 60 50 30 20 0 Time, months 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 OS probability (%) TPC (n = 163) Enhertu (n = 331) Enhertu – leading HER2 ADC with transformational data across multiple tumour types 8 1. Hurvitz SA et al. Lancet. 2023 Jan 14;401(10371):105-117. 2. Modi S et al. N Engl J Med. 2022 Jul 7;387(1):9-20. 3. Meric-Bernstam F et al. J Clin Oncol. 2024 Jan 1;42(1):47-58. 4. Solid tumours including endometrial, cervical, ovarian, bladder, BTC, pancreatic. 5. AstraZeneca press release. https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html. Accessed May 2024. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu). DESTINY-Breast031 HER2+ 2L+ breast cancer DESTINY-Breast06 (HER2-low/ultra-low) – statistically significant, clinically meaningful improvement in PFS5 DESTINY-Breast042 HER2-low 3L+ breast cancer DESTINY-PanTumor023 HER2+ 2L+ tumours4 0.64 OS HR 0.69 OS HR 100 80 60 40 20 0 0 3 6 9 12 15 18 21 24 27 30 33 Time from first dose (months) OS probability (%) All cohorts: IHC 2+ 12.2 (10.7, 13.5) All cohorts: IHC 3+ 21.1 (15.3, 29.6) All cohorts: Total 13.4 (11.9, 15.5) Median OS in months (95% CI) OS events, n (%): 176 (66%) 0 20 40 60 80 100 OS probability (%) Enhertu (n = 261) T-DM1 (n = 263) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 Time, months

• 9. Investor Day • 2024 0 3 6 9 12 15 Time from randomisation (months) 0 20 40 60 80 100 PFS probability (%) Dato-DXd ICC Dato-DXd – potential to displace chemotherapy in NSCLC and breast cancer 9 1. Lisberg A et al. Abstract LBA12 presented at European Society of Medical Oncology 2023. 2. Bardia A et al. Abstract LBA11 presented at European Society of Medical Oncology 2023. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd). First TROP2 ADC in NSCLC to demonstrate statistically significant, clinically meaningful outcomes in Phase III TROPION-Lung011 2L+ Non-squamous NSCLC 0.63 PFS HR TROPION-Breast012 2-3L HR+ HER2- breast cancer 0.63 PFS HR Dato-DXd docetaxel

• 10. Investor Day • 2024 Next-generation bispecifics – going beyond PD-1/PD-L1 inhibitors to establish new IO segments 10 Acronym definitions can be found in Glossary. Collaboration partners: Compugen (rilvegostomig). rilvegostomig (PD-1/TIGIT) volrustomig (PD-1/CTLA-4) Increasing PD-1 activity in PD-(L)1 sensitive tumours Driving survival in CTLA-4 sensitive tumours

• 11. Investor Day • 2024 1. Schmid P et al. Abstract 379MO presented at European Society of Medical Oncology 2023. 2. Papadopoulos KP et al. Abstract OA05.06 presented at the World Conference on Lung Cancer 2023. Acronym definitions can be found in Glossary. 11 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd). ADC + IO combinations proven to transform outcomes Breast cancer Lung cancer Upcoming early-stage data Early data support strong efficacy and safety in metastatic disease BEGONIA (1L TNBC)1 Dato-DXd + Imfinzi TROPION-Lung04 (1L NSCLC)2 Dato-DXd + Imfinzi Dato-DXd + Imfinzi + platinum 50% ORR 77% ORR 79% ORR, 13.8m mPFS I-SPY 2 Neoadj. TNBC, HR+ HER2- breast Dato-DXd + Imfinzi NeoCOAST2.0 Neoadj./adj. NSCLC Dato-Dxd + Imfinzi + platinum 2024 congress presentation Best change from baseline in target lesion size (%) 100 50 # # 0 –50 –100 * Best percent change in sum of diameters from baseline (%)100 80 60 40 20 0 -20 -40 -60 -80 -100 <1% (n=5) 1-49% (n=4) ≥50% (n=5) Treatment ongoing PD-L1 status 100 80 60 40 20 0 -20 -40 -60 -80 -100 Best percent change in sum of diameters from baseline (%) <1% (n=5) 1-49% (n=3) ≥50% (n=5) Treatment ongoing PD-L1 status

• 12. Investor Day • 2024 We have the right portfolio to lead in ADC + IO combinations 12 Phase II trials ongoing include DESTINY-Lung03, TROPION-Lung04, AstraZeneca Phase I/II first-in-human 1L NSCLC, TROPION-Lung02, TROPION-Lung04, NeoCOAST2.0, DESTINY-Gastric03, GEMINI Gastric, TROPION-PanTumor03, BEGONIA, ISPY2. 1. Data on file, not yet published or presented. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd). Illustrative 5-year OS curve Striving to lift OS curves Indications Combinations NSCLC 1L bispecific + Enhertu ± platinum (HER2+)1 bispecific + Dato-DXd ± platinum1 volrustomig + CTx Imfinzi or pembrolizumab + Dato-DXd ± platinum NSCLC Neo-adj. volrustomig + CTx1 Imfinzi + Dato-DXd + platinum1 Gastric 1L bispecific + Enhertu + 5-FU1 bispecific + AZD0901 + 5-FU1 bispecific + CTx1 TNBC 1L Imfinzi + Dato-DXd or Enhertu Imfinzi + CTx TNBC HR+ HER2- breast Neo-adj. Imfinzi + Dato-DXd1 Bladder 1L Endometrial 2-3L bispecific + B7H4 ADC bispecific + Dato-DXd or Enhertu1 Imfinzi + Dato-DXd1 Ongoing novel IO bispecifics + ADC Phase II proof-of-concept data AZ bispecific + ADC (biomarker+) AZ bispecific + ADC AZ bispecific + CTx PDx + ADC/CTx

• 13. Investor Day • 2024 Our commercial strategy to transform patient outcomes 13 Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu); Merck & Co., Inc. (Lynparza). Medicines that matter Building transformative brands Leveraging scale Tumour area leadership Transforming patient care Closing the care gap / Lung Breast Haematology Gastrointestinal GYN/GU Precision diagnostics Patient experience Early detection Guideline-based treatment

• 14. Investor Day • 2024 Leading in lung cancer today and tomorrow 14 Internal estimates. 1. Market share in the US. Commercial delivery to date has helped to transform the lung cancer treatment paradigm Extending leadership tomorrow Metastatic NSCLC EGFR testing rate in Stage IV >80% 73% FLAURA market share1 10+ ongoing Phase III trials Unresectable NSCLC CRT rate of 70% unresectable patients 50% at launch 67% PACIFIC market share1 LAURA Resectable NSCLC Adjuvant treatment rate in early EGFRm 65% ~25% at launch 67% ADAURA market share1 AEGEAN BR.31 | H2 2024

• 15. Investor Day • 2024 Oncology and Haematology – next wave of growth to 2030 and beyond 15 Existing portfolio1 2023 2030 Loss of Exclusivity (Lynparza) Launching NMEs1 AZD0120 AZD0486 camizestrant Dato-DXd rilvegostomig saruparib volrustomig AZN ADCs IRA impact Sustained leadership in disruptive categories ADCs • Radioconjugates • IO bispecifics • cell therapy • T-cell engagers Broad portfolio with unique combination potential and precision medicine expertise Global, differentiated commercial model and footprint Multiple blockbuster medicines across major tumour types and haematology Beyond 2030 $18bn 1. includes select medicines and pipeline opportunities. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Merck & Co., Inc. (Lynparza); Compugen (rilvegostomig). Illustrative only, not to scale

• 16. Investor Day • 2024 We are investing in clinical trials today for future growth 16 Source: Trialtrove. Patient enrolment from collaboration and company sponsored studies averaged over 3 years from start date. Acronym definitions can be found in Glossary. Company 5 Company 6 Company 7 Company 8 Company 3 Company 4 0 5 10 15 20 25 2010 2014 2018 2022 Number of patients 20K 2010 2014 2018 2022 2010 2014 2018 2022 2010 2014 2018 2022 0 5 10 15 20 25 2010 2014 2018 2022 Number of patients 2010 2014 2018 2022 2010 2014 2018 2022 2010 2014 2018 2022 15K 15K 8K 7K 6K 6K 6K Company 2

• 17. Investor Day • 2024 Significant news flow across key medicines through 2025 17 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Compugen (rilvegostomig). 2024 2025 Dato-DXd TROPION-Lung01 OS data, regulatory decision Dato-DXd TROPION-Breast02 1L TNBC data readout Imfinzi EMERALD-2 adj. HCC data readout (≥2025) Imfinzi EMERALD-3 locoregional HCC data readout (>2025) Imfinzi MATTERHORN early-stage gastric data readout Imfinzi ADRIATIC ASCO plenary (June 2024) Tagrisso LAURA ASCO plenary (June’24) Enhertu DESTINY-Breast09 1L HER2+ breast data readout Enhertu DESTINY-Breast06 ASCO LBA (June 2024) Truqap CAPitello-281 dPTEN prostate data readout Imfinzi + ceralasertib LATIFY 2L NSCLC data readout camizestrant SERENA-4/6 1L HR+ HER2- breast data readout (>2025) Multiple Phase III trial initiations planned with IO bispecifics and ADC combinations over next 12-18 months Dato-DXd TROPION-Breast01 regulatory decision Dato-DXd + Imfinzi AVANZAR 1L NSCLC data readout Enhertu DESTINY-Lung04 1L HER2m NSCLC data readout Calquence AMPLIFY 1L CLL data readout Calquence ECHO MCL updated data cut volrustomig + CTx AZ FIH Phase I/II updated data cut rilvegostomig Phase I/II ARTEMIDE-01 1L PD-L1>1% NSCLC update rilvegostomig + CTX Phase I/II GEMINI 1L gastric data cut Imfinzi BR.31 Adjuvant NSCLC data readout Enhertu DESTINY-Breast11 early-stage HER2+ breast data readout Tagrisso + savolitinib SAFFRON 2L MET+ EGFRm data readout

• 18. 18 Investor Day • 2024 Targeted oral therapies

• 19. 19 *Peak Year Revenue, non-risk adjusted across all indications. Acronym definitions can be found in Glossary. Investor Day • 2024 Tagrisso – backbone enables expansion of leadership in EGFRm NSCLC Established backbone in EGFRm NSCLC, expanding across stages of disease • FLAURA2 and ADAURA increase market share and duration of therapy • LAURA establishes new SoC in EGFRm Stage III unresectable • TROPION-Lung14 and TROPIONLung15 advance combinations with ADCs, first with Dato-DXd • Pre-clinical L858R allosteric inhibitor for all-oral combinations Strengthening leadership as backbone TKI in EGFRm NSCLC Early-stage 1L 2L+ ADAURA2 readout ≥2025 LAURA Positive readout ASCO 2024 FLAURA AURA 1-3 NeoADAURA readout H2 2024 New combinations FLAURA2 SAVANNAH/ SAFFRON readout 2024/2025 Building on TKI leadership with powerful combinations, including ADCs ADC combination trials TROPION-Lung14 + Dato-DXd readout >2025 TROPION-Lung15 + Dato-DXd readout >2025 $5bn+* ADAURA

• 20. Investor Day • 2024 Calquence – foundational leadership in haematology 20 *Peak Year Revenue, non-risk adjusted across all indications. Acronym definitions can be found in Glossary. Leading BTK inhibitor in CLL across most major markets • ECHO first-in-class BTKi 1L MCL • AMPLIFY potential best-in-class finite treatment for 1L CLL • ESCALADE potential to expand into lymphoma 1L Increasing leadership with first-in-class combinations 2L+ ELEVATE-TN ASCEND CLL MCL DLBCL AMPLIFY data readout 2025 ECHO positive data readout ESCALADE data readout ≥2025 ACE-LY-004 $3-5bn* Expanding Calquence in MCL and DLBCL

• 21. Investor Day • 2024 Truqap – first and best-in-class AKT inhibitor 21 *Peak Year Revenue, non-risk adjusted across all indications. 1. Biomarker alteration in PIK3CA, AKT1 or PTEN. 2. de novo. Acronym definitions can be found in Glossary. Establishing new SoC, extending benefit from hormone-based therapies • CAPItello-291 strong US launch uptake in biomarker1 positive breast cancer; recent JP approval and positive EU CHMP • CAPItello-281 expand into PTENdeficient metastatic prostate cancer2 First and best-in-class AKT inhibitor across breast and prostate 1L 2L+ HR+ breast cancer mCSPC mCRPC CAPItello-292 data readout >2025 CAPItello-290 data readout H1 2024 CAPItello-281 data readout H2 2024 CAPItello-280 data readout >2025 CAPItello-291 TNBC Establishing Truqap as a combination partner of choice $1-3bn*

• 22. Investor Day • 2024 camizestrant – new endocrine backbone in breast cancer 22 *Peak Year Revenue, non-risk adjusted across all indications. Acronym definitions can be found in Glossary. Establishing the next endocrine therapy backbone • SERENA-4 and SERENA-6 endocrine backbone in combination with CDK4/6 inhibitors in 1L breast cancer • CAMBRIA-1 and CAMBRIA-2 addressing high unmet need for breast cancer patients with intermediate/high-risk earlystage disease Early-stage (adjuvant) Multiple Phase III CDK4/6i combination studies in 1L and early-stage breast cancer 1L HR+ breast cancer CAMBRIA-2 upfront adjuvant camizestrant +/- abemaciclib data readout >2025 SERENA-6 ESR1m camizestrant + CDK4/6i data readout 2025 SERENA-4 camizestrant + palbociclib data readout >2025 CAMBRIA-1 extended adjuvant camizestrant data readout >2025 $5bn+* Extending next-generation oral SERD into early breast cancer

• 23. Investor Day • 2024 saruparib – next-generation PARP inhibitor 23 *Peak Year Revenue, non-risk adjusted across all indications. Yap TA el al. Abstract CT014 presented at American Association for Cancer Research 2024. Acronym definitions can be found in Glossary. Building the next-generation of PARP inhibition • Improved target engagement and safety — Enables longer duration of treatment and lower discontinuation rates • Deep and durable responses Advancing Phase III trials in prostate and breast cancers Castrate-sensitive prostate cancer (HRRm and non-HRRm) PETRA (60mg RP2D)1 showed 9.1m mPFS, 7.3m mDOR in late-line gBRCAm HER2- breast cancer Breast cancer (BRCA/PALB2m) EvoPAR-Prostate01 data readout >2025 EvoPAR-Breast01 data readout >2025 Leverage combinability and improved tolerability with NHAs to advance PARPi + NHA into earlier settings First PARPi to generate headto-head data vs CDK4/6i in 1L HR+ BRCA1/2m/PALB2m setting Additional Phase III trials planned in genitourinary and gynaecological tumours and IO combinations $5bn+*

• 24. 24 Investor Day • 2024 Replacing systemic chemotherapy with ADCs

• 25. Investor Day • 2024 Enhertu – transforming the treatment of breast cancer 25 Enhertu: #1 prescribed therapy in 2L HER2+ and HER2-low breast cancer • Continued demand growth in US and EU, with acceleration in China • Moving Enhertu earlier and broader — 1L and early-stage HER2+ — Chemotherapy-naïve HER2-low and HER2-ultralow HR+ segments with DESTINY-Breast06 Redefining HER2 expression across breast cancer HER2+ breast HR+ HER2-low breast Launches in 2024-2026 will address all stages of HER2+ disease and chemotherapy-naïve HR+ HER2-low mBC Early-stage Metastatic DESTINYBreast11 data readout 2025 DESTINYBreast05 data readout 2025 DESTINYBreast09 data readout 2025 DESTINYBreast03 launched 2022 DESTINYBreast01/02 launched 2019 DESTINY- Breast06 positive data readout ASCO 2024 DESTINYBreast04 launched 2022 *Peak Year Revenue, non-risk adjusted (Product Sales and Alliance Revenue) across all indications. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu). $5bn+*

• 26. Investor Day • 2024 Enhertu – planned Phase III trials with IO combinations 26 Enhertu – moving beyond breast • First ADC tumour-agnostic FDA approval – multiple Phase III studies in 1L HER2+ tumours planned • Enhertu + IO bispecific combinations (rilvegostomig, volrustomig) being tested in Phase II lung and gastric cancers Establishing Enhertu benefit in other solid tumours Moving into 1L with multiple Phase III studies and IO combinations 1L+ Tumour agnostic DESTINY-PanTumor02 launched Ongoing Phase II IO combination trials Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu). NSCLC Gastric Biliary Endo DESTINY-Lung03 +IO ± CTx DESTINY-Lung04 data readout 2025 DESTINY-Lung01/02 launched DESTINY-Gastric03 +IO ± CTx DESTINY-Gastric04 data readout 2025 DESTINY-Gastric01/02 launched DESTINY-BTC01 Phase III trial in planning Exploring Phase III opportunities Exploring Phase III opportunity

• 27. Investor Day • 2024 AVANZAR TROP2 BM+ data readout 2025 Imfinzi TROPIONLung07 data readout >2025 Dato-DXd – potential first TROP2 ADC for NSCLC 27 *Peak Year Revenue, non-risk adjusted (Product Sales and Alliance Revenue) across all indications. 1. Lisberg A et al. Abstract LBA12 presented at European Society of Medical Oncology 2023 2. AGA = actionable genomic alterations in NSCLC (e.g. EGFR, ALK, ROS1, RET, MET, NTRK, BRAF). Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd); Compugen (rilvegostomig). • First TROP2 ADC with positive and clinically meaningful PFS (HR 0.63 2/3L non-sq NSCLC)1 • Unique profile allows combinability with chemotherapy and IO (TROPION-Lung02/04) • Phase III started with novel combinations (rilvegostomig, Tagrisso) (TROPION-Lung10/14/15) • Novel TROP2 QCS biomarkers incorporated into clinical development plan Ongoing Phase II IO or Tagrisso combination trials Early stage 1L 2L+ NeoCOAST 2.0 TROPION- Lung10 TROP2 BM+ data readout >2025 rilvegostomig TROPIONLung08 data readout >2025 NSCLC (non-AGA2) TROPIONLung14 data readout >2025 Tagrisso TROPIONLung15 data readout >2025 Tagrisso TROPIONLung01 OS data readout 2024 EGFRm NSCLC Moving into earlier lines and early-stage NSCLC $5bn+*

• 28. Investor Day • 2024 Dato-DXd – setting a new standard for TROP2 ADCs in breast cancer and beyond 28 1. Bardia A et al. Abstract LBA11 presented at European Society of Medical Oncology 2023. 2.Bladder, ovarian, endometrial, prostate, gastric, colorectal cancers. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd). • Strong efficacy TROPION-Breast01 (0.63 PFS HR in HR+ HER2-), differentiated safety, Q3W dosing1 • Novel IO combinations ongoing – Phase III with Imfinzi (breast cancer), Phase II with IO bispecifics (multiple tumours) Moving into earlier lines and early-stage breast and other Ongoing Phase II Early stage 1L 2L+ TROPION-Breast04 data readout >2025 Imfinzi TROPION-Breast02 data readout 2H24 TNBC TROPION-Breast03 data readout >2025 Imfinzi TROPION-Breast05 data readout >2025 Imfinzi TROPION-Breast01 regulatory decision 2025 HR+ breast TROPION-Pantumour03 IO bispecific Multiple2 IO combination trials

• 29. Investor Day • 2024 Internal investment to deliver industry-leading ADCs 29 Build end-to-end capabilities: ADC conjugation | PK/PD tox models | Biology-translational-clinical development Payloads match disease biology Antibody engineering differentiated novel mAbs and chemistry Targets novel targets via surface proteomics Topoisomerase I Microtubules + alternative MoAs nnAA/ss conjugation bispecific mAb Combat resistance, improve therapeutic index and increase patient coverage Premier database for first-in-class ADC, T-cell engagers and cell therapy targets + + Tumour + normal PDx models Tox species Acronym definitions can be found in Glossary.

• 30. Investor Day • 2024 Proprietary QCS technology can optimise patient selection 30 AI enabled QCS can allow precise assessment of biomarker expression and superior patient selection % tumour cells Positivity cut-off QCS positive responder QCS IHC Distinguish tumour vs normal (better) Quantify membrane vs cytoplasm Associates with internalisation Associates with cytotoxicity Prevalence associates with histology Predictive of clinical efficacy Solutions and opportunity of TROP2 QCS biomarker Acronym definitions can be found in Glossary.

• 31. Investor Day • 2024 Vision to establish at least 2-3 foundational ADCs in major tumours with >80% coverage 31 AZ internal translational data. 1. Coverage inclusive of other targets in development. Acronym definitions can be found in Glossary. 84 95 92 78 100 100 100 NSCLC Colorectal HR+ breast Gastric Ovarian TNBC Endometrial % coverage across AZ ADCs HER2 FRα TROP2 EGFR/MET HER2 CEACAM5/6 HER2 TROP2 B7H4 HER2 CLDN18.2 HER2 TROP2 B7H4 TROP2 HER2 EGFR/MET FRα HER2 TROP2 B7H4 Future potential G7 patients treated with ADCs 310k 213k 169k 107k 61k 47k 40k

• 32. Investor Day • 2024 Growing our portfolio of differentiated ADCs 32 *Peak Year Revenue, non-risk adjusted; includes several medicines with multi-blockbuster potential. Acronym definitions can be found in Glossary. Collaboration partners: Compugen (rilvegostomig). PHASE I PHASE II PHASE III Endometrial, ovarian, breast, biliary NSCLC, HNSCC, CRC Ovarian, NSCLC Gastric, GEJ, pancreatic R/R multiple myeloma Tumors Acute myelocytic leukemia, myelodysplastic syndrome AZD8205 B7H4 TOP1i AZD9552 EGFR/cMET TOP1i AZD5335 FRα TOP1i AZD0305 GPRC5D MMAE AZD9829 CD123 TOP1i MMAE CLDN18.2 AZD0901 Claudin 18.2 MMAE GEMINI Phase II: AZD0901 + rilvegostomig 1L CLDN18.2+ Gastric AZD0901 Phase I dose escalation 2L+ CLDN18.2-positive gastric/GEJ Leading CLDN18.2 ADC in Phase III gastric cancer $5bn+* • CLARITY-01 (Phase III AZD0901 2L+ CLDN18.2+ gastric) ongoing • AZD0901 + rilvegostomig being tested in Phase II 1L CLDN18.2+ gastric 60 40 20 0 -20 -40 -60 -80 -100 Maximum decrease from baseline in sum of longest diameter (%) PD PD PD PD PD PD PD PD PD NE SD PD SDPD PD PD NE PD SDPD PD NE PD SD PD SDSD SD SD PD SD SD SD PDSDPD SD SD SD SD PD SD SD SD SD SDSD PD SD SD PRPRPR PR * PR PR PR * PR PR PR PR PR PR PR PR PR PR PR PRPRPR PR PR PR PR PR PR PR PRPRPR PR PR PR PR PR CRPRCR -30 20% Patients

• 33. 33 Investor Day • 2024 Expanding beyond PD-(L)1 with next-generation immuno-oncology

• 34. Investor Day • 2024 Imfinzi and Imjudo – IO leadership in GI cancer, NSCLC and beyond 34 *Peak Year Revenue, non-risk adjusted across all indications. 1. Market share of new patients 6 months from launch. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd). • Establishing Imfinzi + Dato-DXd in NSCLC and TNBC • Building on CASPIAN success with ADRIATIC in LS-SCLC • Strengthening leadership in GI — Build on HIMALAYA with EMERALD-1, -2 and -3 — Move into early gastric with MATTERHORN — ~75% market share1 in 1L BTC with TOPAZ-1 Significant potential across tumours NSCLC SCLC HCC BTC Breast Early-stage 1L TROPION-Breast03 data readout >2025 + Dato-DXd TROPION-Breast04 data readout >2025 + Dato-DXd TROPION-Breast05 data readout >2025 + Dato-DXd TOPAZ-1 launched 2022 HIMALAYA launched 2022 CASPIAN launched 2020 POSEIDON launched 2022 PACIFIC launched 2018 PACIFIC-4 data readout >2025 AEGEAN regulatory decision BR.31 data readout H2 2024 PACIFIC-8, -9 data readout >2025 AVANZAR + Dato-DXd data readout 2025 ADRIATIC positive readout ASCO 2024 EMERALD-1 positive data readout ASCO GI EMERALD-2 data readout ≥2025 EMERALD-3 data readout ≥2025 DELLphi-305 data readout >2025 ADC combination trials Gastric MATTERHORN data update 2025 $5bn+*

• 35. Investor Day • 2024 rilvegostomig – potential to displace single agent PD-1/PD-L1 across IO sensitive tumours 35 *Peak Year Revenue, non-risk adjusted across all indications. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Compugen (rilvegostomig). Demonstrating higher anti-tumour activity than αPD-1/TIGIT bivalent combinations or αPD-1 monotherapy rilvegostomig (PD-1/TIGIT) Differentiated bispecific format Updated Phase I/II data to be presented at medical congress in 2024 Differentiated clinical development programme Leveraging combinations with our robust ADC pipeline Current ADC combinations • Enhertu • Dato-DXd • AZD0901 (CLDN18.2) Future ADC combinations • AZD8205 (B7H4) • AZD9592 (EGFR/cMET) • AZD5335 (FRα) $5bn+* Isotype Ctl anti-PD-1 anti-PD-1 + anti-TIGIT rilvegostomig 2000 1500 1000 500 Tumour Volume (mm3) 0 0 10 20 30 40 Study days i.p. dosing

• 36. Investor Day • 2024 rilvegostomig – accelerating development programme 36 Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Compugen (rilvegostomig). Initiating up to 10 pivotal trials with novel combinations across NSCLC, GI, and GU/GYN tumours TROPION-Lung10 | Phase III rilvegostomig ± Dato-DXd vs pembrolizumab TROPION-Lung10 1L PD-L1 ≥ 50% non-squamous NSCLC rilvegostomig + Dato-DXd rilvegostomig pembrolizumab Dual primary endpoints mPFS and OS in TROP2 BM+

• 37. Investor Day • 2024 volrustomig – potential to displace single agent PD-(L)1 across CTLA-4 sensitive tumours 37 *Peak Year Revenue, non-risk adjusted across all indications. 1. Ahn MJ et al. Abstract LBA56 presented at European Society of Medical Oncology 2022. Acronym definitions can be found in Glossary. volrustomig Increases CTLA-4 therapeutic index Updated Phase I/II data to be presented at medical congress in 2024 volrustomig + CTx Showed depth of response Addressing unmet need for PD-L1-low patients Anti-PD-1 Fab Anti-CTLA-4 Fab Knob-into-hole IgG1-TM Fc Peripheral CD4+ T-cell proliferation of volrustomig ≥500mg is greater than Imjudo 3mg/kg + Imfinzi 10mg/kg • 44% ORR (PD-L1<1%) • 56% ≥30% reduction in target lesions • 20% TEAEs (discontinuation rate) Phase I/II volrustomig + CTx 1L non-sq NSCLC1 Phase III ongoing in 1L PD-L1 <50% NSCLC Comprehensive ongoing Phase III programme • eVOLVE-Meso • eVOLVE-HNSCC • eVOLVE-Cervical eVOLVE-Lung02 1L PD-L1<50% NSCLC volrustomig + CTx pembrolizumab + CTx $5bn+* PD-L1 NE PD-L1 <1% PD-L1 1-49% PD-L1 >50% Best change from baseline (%) 0 -10 -20 -30 -40 -50 -60 -70 -80

• 38. 38 Investor Day • 2024 Leadership in breast, NSCLC and gastric cancers

• 39. Investor Day • 2024 Extending leadership in NSCLC and breast cancer AstraZeneca select NSCLC portfolio AstraZeneca select breast cancer portfolio IO sensitive NSCLC EGFRm NSCLC HER2m Imfinzi PACIFIC-8/9 AEGEAN, BR.31 PACIFIC-4 Dato-DXd to replace CTx TROPION-Lung01 AVANZAR, TROPION-Lung07, -08 Dato-DXd ± Tagrisso HER2+ HR+ TNBC Expanding Enhertu Enhertu to replace trastuzumab + CTx DESTINY-Breast11, -05, -09 Enhertu and DatoDXd to replace CTx DESTINY-Breast04, -06, TROPION-Breast01 camizestrant to become the backbone ET of choice CAMBRIA-1/2, SERENA-4/6, eVOPAR-Breast01 (BRCA1/2, PALB2) Truqap addresses key drivers of resistance CAPItello-292 CAPItello-290 Dato-DXd ± Imfinzi replace IO + CTx TROPION-Breast04, -03, -05, -02 Truqap established SoC CAPItello-291 Tagrisso ± CTx FLAURA, FLAURA-2 ADAURA, ADAURA-2, Neo-ADAURA LAURA TROPION-Lung01 TROPION-Lung-15, -14 Early Metastatic Early Metastatic DESTINY-Breast02, -03, -06 Enhertu For HER2m and HER2+ Novel combinations Acronym definitions can be found in Glossary. 39 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Compugen (rilvegostomig). Next-generation IO bispecifics to replace PD-(L)1 eVOLVE-Lung02, NeoCOAST2.0 TROPION-Lung10

• 40. Investor Day • 2024 Building leadership position in gastric cancer Targeting key segments with bispecifics + ADCs within a ~$12bn market1 Stg. I-III Metastatic Est. epi (G7) 48-100K Early-stage 2L 3L 58-128K 30-71K HER2-high ~20% HER2-low ~11% HER2-low/ CLDN18.2+ ~11% CLDN18.2+ ~35% Other MATTERHORN Enhertu Established SoC Enhertu Established SoC CLARITY-01 established SoC 1. Reflects projected estimate of gastric cancer market across G7 countries (ex-China). G7 drug-treated patients based on data from Cerner, DRG, and Epic Oncology (early perioperative and 1L-2L metastatic disease). Duration of therapy calculated based on mPFS or time of fixed regimen. AZN internal pricing estimates used for monotherapy and combination therapies and market potentials assume maximum novel share and testing rates based on Cerner analogues. Acronym definitions can be found in Glossary. 40 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Compugen (rilvegostomig). AZD0901 (CLDN18.2) replaces systemic chemotherapy 1L 91-170K DESTINY-Gastric03 Enhertu replaces trastuzumab in HER2-high GEMINI Phase I/II Next-generation IO bispecifics (volrustomig, rilvegostomig) replace PDx Opportunity to combine with AZD0901 Establishing IO in early gastric cancer

• 41. 41 Investor Day • 2024 Next-wave haematology portfolio

• 42. Investor Day • 2024 Eight haematology assets spanning multiple modalities Cell therapy BCMA/CD19 αCD19 αCD3 Fc Tail Immune engagers CD19, CD20 ADCs CD123, GPRC5D CD123 GPCR5D CD222 Tumour drivers BTK, IRAK4C Epigenetics PRMT5 42 Acronym definitions can be found in Glossary.

• 43. Investor Day • 2024 Haematology – combinations will drive increased cure 43 1. 2030 incidence: Cerner Enviza. 2. PFS/EFS rates based on SoC in largest patient segment from landmark clinical studies. Acronym definitions can be found in Glossary. DLBCL/FL, MCL CLL B-ALL B-cell lymphoid malignancies 130k 44k 10k 50-70% 70% 35% adult 85% paed. AZD0486 CD19/CD3 TCE Calquence BTKi Multiple myeloma 79k 55% AZD0305 GPRC5D ADC AZD0120 BCMA/CD19 CAR-T Acute myeloid leukaemia 43k 10% AZD9829 CD123 ADC Estimated new cases (G7, 2030)1 1L 5-year PFS/EFS rates2 Building regimens around core assets

• 44. Investor Day • 2024 *Peak Year Revenue, non-risk adjusted across all indications. 1. Gaballa S et al,. Abstract 1662 presented at American Society of Hematology 2023. 2. Michot JM et al. Cancer Drug Resist. 2021 Mar 26;4(3):710-718. 3. Lunsumio 44 (mosunetuzumab-axgb) US Prescribing information. Acronym definitions can be found in Glossary. AZD0486 (CD19/3 T-cell engager) – demonstrated high responses in B-cell lymphoma, now in Phase II Targeting CD19 vs CD20 Engineered to reduce toxicity and increase stability Demonstrated strong early efficacy data r/r follicular lymphoma AZD0486 ≥2.4mg double step-up1 CD20xCD3 TCE3 ORR 88% (15/17) 80% CR 82% (14/17) 60% Historical benchmark αCD19 High-affinity heavychain-only domain Activating αCD3 Unique binding site reduce cytokine release Silenced IgG4 Fc tail Prevents nonspecific binding, antibodydependent cellular cytotoxicity, and confers a long half-life 29% CRS (all Gr1)1 Q2W + IV dosing (SC in development) CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD20 CD20 CD20 CD20 CD20 CD3 AZD0486 rituxan CD20-TCE CD3 Combination potential up to 16% antigen loss across lymphomas for CD19 and CD202 CD19 expressed across broader range of B-cells CD19 CD20 $5bn+*

• 45. Investor Day • 2024 AZD0120 (GC012F) – pioneering BCMA/CD19 dual-targeting CAR-T cell therapy, Phase III ready 45 *Peak Year Revenue, non-risk adjusted across all indications. Data cut-off 1 October 2023. 1. MRD was tested by Euroflow at a sensitivity of 106. Chen X et al. Abstract 1022 presented at American Society of Hematology 2023. Acronym definitions can be found in Glossary. Differentiated cell therapy product profile • Dual BCMA/CD19 CAR-T targets both myeloma and progenitor cells — BCMA targets plasma cells with proven efficacy in myeloma — CD19 targets progenitor cells – deep durable response • Clean safety profile for early-stage disease — Younger, fitter T-cells mean lower cell dose required — No neurotoxicity or ICANs across existing data (N=15) • Gracell FAST-CAR manufacturing accelerated to 24-36 hours Efficacy in 1L high-risk myeloma $5bn+* 0 25 50 75 100 All patients (N=22) Evaluable patients (N=15) Patients (%) VGPR CR/sCR MRD- MRD+ 12 month MRD1 100% ORR 100% CR/sCR 95%

• 46. 46 Investor Day • 2024 Transforming outcomes with next-generation therapies

• 47. Investor Day • 2024 Building leadership in Radioconjugates 47 Fusion Pharmaceuticals acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Acronym definitions can be found in Glossary. Becoming a key backbone modality with significant combination potential Potential to redefine use or replace traditional radiation therapy Current state Future state Unlocking novel target space Small molecule VHH Peptide

• 48. Investor Day • 2024 OS HR 0.62 Patients alive (%) 0 10 20 30 40 50 60 70 80 90 100 0 2 4 6 8 10 Months since randomisation 12 14 16 18 20 22 24 26 28 30 32 177Lu-PSMA-617 + standard care Standard care alone FPI-2265 (PSMA-α) – leading alpha Radioconjugate in prostate cancer 48 Fusion Pharmaceuticals acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. 1. Morris MJ et al. Abstract LBA4 presented at American Society of Clinical Oncology 2021. 2. Sathekge MM et al, Lancet Oncol 2024; 25:175-83. 3. Patel S et al. Abstract LB155 presented at American Association for Cancer Research 2021; includes IGF1R data. Acronym definitions can be found in Glossary. PSMA proven prostate cancer target α emission more potent than β emission Pursuing IO combinations Lutetium PSMA β-emitting RIC VISION Phase III mCPRC1 Retrospective meta-analysis: PSMA⍺ > PSMAβ (PSA50 57% vs 46%)2 Immunogenic cell death from αRIC can drive RIC + IO combinations Potency 3 Energy deposited per unit length (LET,keV/um) ⍺ β 80-300 0.2 0 5 10 0 4 8 12 16 20 24 28 Days after treatment initiation Vehicle control Anti-PD-1 mAb (5 mg/kg) [ 225Ac]-TAT only [ 225Ac]-TAT + anti-PD-1 mAb Change from baseline in PSA (%) Patients CT26 relative tumour volume (RTV)

• 49. Investor Day • 2024 Building leadership in cell therapy 49 Bringing the curative potential of cell therapy with several potential launches before 2030 Advancing seven medicines into clinical trials Haematology/ autoimmune Solid tumours T-cell receptor therapies • BCMA/CD19 • GPC3 dnTGFb • STEAP2 dnTGFb • Claudin 18.2 dnTGFb • Individualised TCRs • TP53 R175H • KRASG12D Multiple myeloma, SLE Liver cancer Prostate cancer Gastric cancer Colorectal, lung cancer Pancreatic, colorectal, lung cancer Pancreatic, colorectal, lung cancer Highest quality cells in spec Capacity to meet clinical scale and potential commercial demand Improved profitability through decreased COGS Acronym definitions can be found in Glossary.

• 50. 50 Investor Day • 2024 Concluding remarks

• 51. Investor Day • 2024 *Peak Year Revenue, non-risk adjusted, for some medicines includes Product Sales and Alliance Revenue and across all indications. Acronym definitions can be found in Glossary. 51 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Merck & Co., Inc. (Lynparza); Compugen (rilvegostomig). Multiple high-value opportunities and rich near-term catalyst path support growth to 2030 and beyond Growth drivers to 2030 Upcoming Key Phase II and Phase III readouts Dato-DXd TROPION-Lung01 OS data readout camizestrant SERENA-4/6 1L HR+ HER2- (>2025) volrustomig + CTx FIH Phase I/II updated data cut Dato-DXd TROPION-Breast02 1L TNBC data readout Enhertu DESTINY-Breast11 early-stage HER2+ rilvegostomig Phase I/II ARTEMIDE 1L PD-L1>1% NSCLC data cut Dato-DXd AVANZAR 1L NSCLC data readout Enhertu DESTINY-Breast09 1L HER2+ rilvegostomig + CTx Phase I/II GEMINI 1L gastric data cut Truqap CAPItello-281 dPTEN prostate data readout Calquence AMPLIFY 1L CLL $5bn+ PYR* $3-5bn PYR* AZN ADCs AZD0486 AZD0120 Dato-DXd saruparib rilvegostomig volrustomig / camizestrant

• 52. 52 Investor Day • 2024 Appendix

• 53. Investor Day • 2024 AstraZeneca in lung cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 53 All numbers are approximate. Illustrative settings and populations, not to scale. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig). Leading the future of lung cancer treatment • Establishing Tagrisso as backbone TKI in EGFRm • Imfinzi leading IO in unresectable • Advancing best-in-class ADCs to replace systemic chemotherapy • Delivering next-wave bispecifics to improve on PD-(L)1 • Developing novel combinations, including IO & Tagrisso + ADCs • Investing behind new technologies and platforms, including cell therapy and testing/screening APPENDIX | Oncology tumour maps EGFRm c.16% IO sensitive c.70% Stg. I-III metastatic 1L 2L+ Est. epi (G7) ~200K ~30K ~70K ~350K ~290K HER2m c.2% Other tumour drivers c.12% Imfinzi / Osi w/ SBRT PACIFIC-4 Imfinzi combos PACIFIC-8, -9 improvements across PD-L1 spectrum Stg. I-II Stg. III unresectable CRT à Tagrisso LAURA Imfinzi AEGEAN volrustomig + CTx Imfinzi + Dato + plat NEOCOAST-2 Enhertu DESTINY-Lung04 Imfinzi + Imjudo + CTx POSEIDON resectable CRT à Imfinzi PACIFIC Dato-DXd +/- Tagrisso TROPION-Lung15/ 01 AZD9592 (EGFR/cMET ADC) EGRET Dato-DXd TROPION-Lung01 Imfinzi + ceralasertib LATIFY savolitinib + Tagrisso SAFFRON/SAVANNAH CRT à Imfinzi PACIFIC Tagrisso FLAURA AZD9592 (EGFR/cMET ADC) EGRET Enhertu + IO + CTx DESTINY-Lung03 established SoC Dato-DXd + IO +/- Platinum TROPION-Lung08/TROPION-Lung07/AVANZAR sabestomig (PD-1/TIM3) Enhertu DESTINY-Lung02 volrustomig + CTx eVOLVE-Lung02 Tagrisso neoADAURA Tagrisso ADAURA Dato-DXd + Rilvegostomig TROPION-Lung10 Tagrisso + CTx FLAURA-2 Dato-DXd + Tagrisso TROPION-Lung14

• 54. 54 Investor Day • 2024 All numbers are approximate. Illustrative settings and populations, not to scale. All numbers for epi are drug-treated. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd). AstraZeneca in breast cancer Ambition to eliminate breast cancer as a cause of death APPENDIX | Oncology tumour maps gBRCAm 5% of HR-positive 15% of TNBC HER2-positive 15-20% HR-positive 65-75% TNBC 10-15% Est. epi (G7) 520k 130k 100k 70k 55k 1st line 2nd line 3rd line 4th line + Early drug-treated Neoadjuvant Adjuvant Metastatic drug-treated CTx à Lynparza OlympiA NSTà residual disease à Enhertu DESTINY-Breast05 Enhertu ± THP DESTINY-Breast11 NST à residual disease à Dato-DXd ± Imfinzi TROPION-Breast03 CTx à AI (± CDK4/6i) 2-5 yrs à camizestrant CAMBRIA-1 Good outcomes with current SoC CTx à camizestrant (± CDK4/6i) CAMBRIA-2 Enhertu DESTINY-Breast03 Lynparza OlympiAD Enhertu DESTINY-Breast02 camizestrant + CDK4/6i SERENA-4 AI + CDK4/6i à camizestrant + CDK4/6i SERENA-6 ESR1m 35% Enhertu ± pertuzumab DESTINY-Breast09 Dato-DXd TROPION-Breast02 Dato-DXd TROPIONBreast01 PD-L1- 60% RECURRENCE established SoC Dato-DXd + Imfinzi TROPION-Breast05 PD-L1+ 40% Dato-DXd + Imfinzi TROPIONBreast04 Truqap + Faslodex CAPItello291 PIK3CA, AKT1, PTEN alt.40% Truqap + paclitaxel CAPItello290 Truqap + Faslodex + CDK4/6i CAPItello292 saruparib + camizestrant EvoPAR-Breast01 tBRCAm, PALB2m 9% Low risk Enhertu DESTINY-Breast06 HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25% Enhertu DESTINYBreast04 HER2-low (1+, 2+) 60% HER2-low (1+, 2+) 35% Int/High risk

• 55. 55 Investor Day • 2024 Glossary – 1 of 2 CLL chronic lymphocytic leukaemia cm centimetre CM cardiomyopathy cMET c-mesenchymal epithelial transition factor COPD chronic obstructive pulmonary disease CRwNP chronic rhinosinusitis with nasal polyps CSA-AKI cardiac surgery-associated acute kidney injury ctDNA circulating tumour DNA CTLA4 cytotoxic T-lymphocyte associated protein 4 CTx chemotherapy CV cardiovascular CVRM Cardiovascular, Renal and Metabolism DDR DNA damage response DGF delayed graft function DLBCL diffuse large B-cell lymphoma dnTGFb dominant-negative transforming growth factor-beta dPTEN phosphatase and tensin homolog deficient EBITDA Earnings before interest, tax, depreciation and amortisation EGFR epidermal growth factor receptor eGFR estimated glomerular filtration rate EGPA eosinophilic granulomatosis with polyangiitis EM Emerging Markets EOS eosinophil EPI epigenetics EPS earnings per share ERoW Established Rest of World ESR1 estrogen receptor alpha ESRD end stage renal disease ETA RA endothelin receptor A antagonist ETARA endothelin receptor A antagonist FDC fixed dose combination FeNO fractional exhaled nitric oxide FL Follicular lymphoma FLAP 5-lipoxygenase activating protein FRα folate receptor alpha FX foreign exchange G7 US, Japan, EU5 GA geographic atrophy GLP-1/glu glucagon-like peptide 1 receptor/glucagon dual peptide agonist GLP-1RA glucagon-like peptide 1 receptor agonist gMG generalised myasthenia gravis GN glomerulonephritis GPC3 Glypican-3 GPRC5D G protein-coupled receptor class C group 5 member D GU genitourinary GYN gynaecologic HbA1c glycated haemoglobin HCC hepatocellular carcinoma HER2 human epidermal growth factor receptor 2 HF heart failure HFrEF heart failure with reduced ejection fraction HK hyperkalaemia HLR high-level results hMPV human metapneumovirus HNSCC head and neck squamous cell carcinoma HR hazard ratio HR+ hormone receptor positive HRR homologous recombination repair HSCT-TMA hematopoietic stem cell transplantation-associated thrombotic microangiopathy i.v. intravenous IBD inflammatory bowel disease ICS inhaled corticosteroid ICU intensive care unit IgAN IgA nephropathy IIT investigated initiated trial iJAK1 inhaled Janus kinase IL-33 interleukin-33 IL-5 interleukin-5 IND investigational new drug IO Immuno-oncology IPF idiopathic pulmonary fibrosis IRA Inflation Reduction Act iTSLP inhaled thymic stromal lymphopoietin ITT intent to treat IVIg intravenous immunoglobulin 1L, 2L, 3L first-, second-, third-line 6MWT 6-minute walk test AAV adeno-associated virus ACE angiotensin-converting enzyme AChR+ acetylcholine receptor-positive ADC antibody conjugate ADsCa albumin-adjusted serum calcium AER annual exacerbation rate AEs adverse effects AGA actional genomic alteration aHUS atypical haemolytic uraemic syndrome AL amyloidosis light-chain amyloidosis AML acute myelogenous leukaemia AMR antibody mediated rejection anti-PCD anti plasma cell dyscrasia AQP4+ aquaporin-4 antibody positive ARB angiotensin receptor blockers ASCO American Society of Clinical Oncology ASI aldosterone synthase inhibitor ASO antisense oligonucleotide ATTR-CM transthyretin amyloid cardiomyopathy ATTR-PN transthyretin amyloid polyneuropathy B-ALL B-cell acute lymphoblastic leukaemia BCMA B-cell maturation antigen BRCA breast cancer gene BTC biliary tract cancer BTKi Bruton's tyrosine kinase C5 complement component 5 CAGR compound adjusted growth rate cAMR chronic antibody-medicated rejection CAR-T chimeric antigen receptor T-cells CD19 Cluster of differentiation 19 CD3 Cluster of differentiation 3 CDK4/6i cyclin-dependent kinase 4/6 inhibitor CER constant exchange rates CI confidence interval CKD chronic kidney disease CLDN 18.2 Claudin-18.2

• 56. 56 Investor Day • 2024 Glossary – 2 of 2 NST neoadjuvant systemic treatment NT-proBNP N-terminal pro-B-type natriuretic peptide NYHA New York Heart Association oGLP1 oral glucagon-like receptor peptide 1 oPCSK9 oral protein convertase subtilisin/kexin type 9 ORR overall response rate oRXFP1 oral relaxin family peptide receptor 1 OS overall survival PALB2m partner and localizer of BRCA2 PARP1 poly(ADP-ribose) polymerase-1 PARPi poly-ADP ribose polymerase inhibitor PD1 programmed cell death protein 1 PD-L1 programmed cell death ligand 1 PFS progression free survival PIK3CA phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit PK/PD pharmacokinetic/pharmacodynamic PLEX plasma exchange PN polyneuropathy PNH paroxysmal nocturnal haemoglobinuria PNH-EVH paroxysmal nocturnal haemoglobinuria with extravascular haemolysis PNPLA3 phospholipase domain-containing protein 3 PP plasmapheresis PSA prostate-specific antigen PSA50 prostate-specific antigen 50 PTEN phosphatase and TENsin homolog deleted on chromosome 10 PYR peak year revenue Q2W every 2 weeks Q4W every 4 weeks Q8W every 8 weeks QCS quantitative continuous scoring QoQ quarter on quarter R&D research and development R&I Respiratory and Immunology r/r relapsed/refractory RA rheumatoid arthritis RAGE receptor for advanced glycation end products RC radioconjugates RP2D recommended Phase II dose RSV respiratory syncytial virus s. asthma severe asthma s.c. subcutaneous SABA short acting beta agonist SBP systolic blood pressure SBRT stereotactic brain radiotherapy SC subcutaneous SG&A Selling, General and Administrative SGLT2i sodium/glucose cotransporter 2 inhibitor sK serum potassium SLE systemic lupus erythematosus SoC standard of care ST2 suppression of tumorigenicity 2 Stg. I/II/III Stage I/II/III Stg. III u/r NSCLC Stage III unresectable non-small cell lung cancer T2D type-2 diabetes T8 US, China, Japan, EU5 TCE T-cell engager tCO2e tonnes of carbon dioxide equivalent TCR T-cell receptor TDR tumour drivers and resistance TIGIT T-cell immunoreceptor with immunoglobulin and ITIM domains TIM-3 T-cell immunoglobulin and mucin domain-containing protein TKI tyrosine kinase inhibitor TNBC triple negative breast cancer TP53 tumour protein 53 Treg Regulatory T-cell TROP2 trophoblast cell surface antigen 2 TTR transthyretin u/r HTN uncontrolled or treatment resistant hypertension UACR urinary albumin/creatinine ratio ULN upper limit of normal V&I Vaccines and Immune Therapies VLP virus-like particle K+ potassium KCCQ Kansas City Cardiomyopathy Questionnaire LA amylin long-acting amylin LABA long-acting beta 2-agonists LAMA long-acting muscarinic antagonists LCM life cycle management LDL-C low-density lipoprotein cholesterol LN lupus nephritis LoE loss of exclusivity LS-SCLC limited stage small-cell lung cancer LV left ventricular mAb monoclonal antibody MASH metabolic dysfunction-associated steatohepatitis, also known as nonalcoholic steatohepatitis (NASH) MASLD metabolic dysfunction-associated steatotic liver disease mBC metastatic breast cancer MCL mantle cell lymphoma mDOR median duration of response mg/dL milligrams per decilitre MGFA Myasthenia Gravis Foundation of America mHSPC metastatic hormone sensitive prostate cancer mL millilitre MM multiple myeloma MoA mechanism of action MPO myeloperoxidase MRA mineralocorticoid receptor antagonist MRM mineralocorticoid receptor modulator n/m not material NBRx new-to-brand prescription Neo-adj neoadjuvant NF1-PN neurofibromatosis type 1-plexiform neurofibromas ngSERD next-generation oral selective estrogen receptor degrader NHA novel hormone agent NME new molecular entity NMOSD neuromyelitis optica spectrum disorder NP nasal polyps NRDL national reimbursement drug list NSCLC non-small cell lung cancer